- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Genetic Immunity, a US/Hungarian clinical-stage Company focused on the development of its patented nanomedicines for targeted immune amplification, announced today that the Company will be presenting at the 2008 Bio International Convention to be held June 17-20, 2008 at the San Diego Convention Center in San Diego, CA. The Company's President and Chief Executive Officer, Dr. Julianna Lisziewicz, is scheduled to present at the following times:
-- Wednesday, May 18 at 2:00 p.m. (PT): Dr. Lisziewicz will present an overview of Genetic Immunity's nanomedicine technology platform and clinical programs on as part of the infectious disease tract in room 5B. -- Thursday, June 19th at 2:00 p.m. (PT): Dr. Lisziewicz will represent Genetic Immunity in an international case study, "Biotechnology in Hungary: Mission Possible," in room 26 AB.
For more information on this event please visit: www.bio2008.org.
While at the conference Genetic Immunity will discuss three partnering opportunities. The first is focused on DermaVir Patch, which is the Company's lead nanomedicine candidate for the treatment for HIV/AIDS. This topically delivered nanomedicine is designed to amplify HIV-specific memory T cell responses in order to kill HIV-infected cells specifically while leaving the healthy cells intact.
The second opportunity is DermaPrep, which is a novel and proprietary medical device that supports the topical delivery of macromolecules to lymph nodes. DermaPrep is designed to mimic the body's response and has demonstrated proof of concept with through development of the DermaVir Patch.
The third partnering option is the Company's patented NanoComp nanoformulation technology that includes disease-specific, plasmid DNA-encoded antigens. It is designed to improve the immunigenicity of antigens and induce effective immune responses. NanoComp has also demonstrated proof of concept with the DermaVir Patch, which includes HIV-specific plasmid DNA encoded antigens.
About Genetic Immunity
Genetic Immunity is a US/Hungarian clinical stage biopharmaceutical company establishing leadership in Nanomedicines for targeted immune amplification. Nanomedicine, an offshoot of nanotechnology, refers to highly specific medical intervention at the molecular scale for curing diseases or repairing damaged tissues. The Company aims to discover, develop and commercialize topically administered nanomedicines that can create new markets for treating infectious diseases, cancer and allergies. These indications represent a significant unmet medical need and the potential for alternative treatment approaches. The DermaVir Patch, Genetic Immunity's lead nanomedicine candidate, is in Phase II clinical development and could be the first nanomedicine immune therapy for HIV-infected individuals. The DermaVir Patch has demonstrated excellent safety, immunogenicity and antiviral efficacy in preclinical studies. Phase I/II trials to date have confirmed safety and tolerability and indicate the induction of long-lasting HIV-specific memory T cells.
About the Nanomedicine Technology Platform
Genetic Immunity's nanomedicine immune amplification platform technology is comprised of two principal components: NanoComp and DermaPrep. NanoComp is a patented nanoformulation technology that includes disease-specific plasmid DNA encoded antigens. DermaPrep is the topical administration device that delivers NanoComp into a patient's lymph node dendritic cells to induce T cell mediated immune responses that can treat a broad spectrum of diseases. These two components together make up the DermaVir Patch. The plasmid DNA within DermaVir Patch's NanoComp nanoparticles is specific to HIV and topically delivered via DermaPrep to amplify the immune system to kill only HIV-infected cells.
For more information, please click here
The Ruth Group Investors
Copyright © PR Newswire Association LLC.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Stealth nanocapsules kill Chagas parasites in mouse models June 22nd, 2016
Call for NanoArt and Art-Science-Technology Papers June 9th, 2016
Novel gene therapy shows potential for lung repair in asthma May 18th, 2016